• Tofersen Linked to Slow but Positive ALS Outcomes

    1 day ago - By Medscape

    An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.
    Medscape Medical News
    Read more ...